Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Gross Profit: 2017-2025

Historic Gross Profit for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to $2.8 million.

  • Aclaris Therapeutics' Gross Profit fell 25.22% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 44.46%. This contributed to the annual value of $15.9 million for FY2024, which is 42.76% down from last year.
  • Aclaris Therapeutics' Gross Profit amounted to $2.8 million in Q3 2025, which was up 118.78% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Gross Profit ranged from a high of $18.1 million in Q3 2022 and a low of $298,000 during Q1 2022.
  • For the 3-year period, Aclaris Therapeutics' Gross Profit averaged around $4.4 million, with its median value being $2.1 million (2024).
  • In the last 5 years, Aclaris Therapeutics' Gross Profit spiked by 3,131.25% in 2022 and then crashed by 56.22% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Gross Profit (Quarterly) stood at $352,000 in 2021, then skyrocketed by 1,853.41% to $6.9 million in 2022, then skyrocketed by 144.98% to $16.8 million in 2023, then slumped by 49.50% to $8.5 million in 2024, then fell by 25.22% to $2.8 million in 2025.
  • Its Gross Profit was $2.8 million in Q3 2025, compared to $1.3 million in Q2 2025 and $949,000 in Q1 2025.